Infect Agent Cancer. 2010; 5: 18.
Published online 2010 October 12. doi: 10.1186/1750-9378-5-18. PMCID: PMC2964600 Copyright ©2010 Pelser et al; licensee BioMed Central Ltd.


Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30

Colleen Pelser,1,2 Jaap Middeldorp,3,4 Sam M Mbulaiteye,1 Carmela Lauria,5 Angelo Messina,6 Enza Viviano,7 Nino Romano,7 Francesco Vitale,7 and James J Goedert1


ABSTRACT

Background
To clarify the immunological alterations leading to classical Kaposi sarcoma (cKS) among people infected with KS-associated herpesvirus (KSHV).

Methods
In a population-based study of 119 cKS cases, 105 KSHV-seropositive controls, and 155 KSHV-seronegative controls, we quantified plasma soluble cluster of differentiation (sCD) levels and antibodies against Epstein-Barr virus nuclear antigen-1 (anti-EBNA-1) and viral capsid antigen (anti-VCA). Differences between groups in prevalence of low-tertile anti-EBNA-1 and high-tertile anti-VCA were compared by logistic regression. Continuous levels between groups and by presence of cKS co-factors among controls were compared by linear regression and Mann-Whitney-Wilcoxon methods.

Results
Comparisons of cKS cases to seropositive controls and of seropositive to seronegative controls revealed no significant differences. However, controls with known cKS cofactors (male sex, nonsmoking, diabetes and cortisone use) had significantly lower levels of anti-EBNA (P = 0.0001 - 0.07) and anti-VCA (P = 0.0001 - 0.03). Levels of sCD26 were significantly lower for male and non-smoking controls (Padj ? 0.03), and they were marginally lower with older age and cortisone use (Padj ? 0.09).
Conclusions
Anti-EBV and sCD26 levels were associated with cofactors for cKS, but they did not differ between cKS cases and matched controls. Novel approaches and broader panels of assays are needed to investigate immunological contributions to cKS.

Articles from Infectious Agents and Cancer are provided here courtesy of BioMed Central